Sort
11,323 grants matching “glioblastoma”
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$543,527James R. Heath · Institute For Systems Biology · U01 · FY2017 · CA
lncRNA regulation of glioblastoma progression and therapeutic resistance
$543,237Jennifer S Yu · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · NS
Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)
$543,207Jeremy N Rich · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Development of a Therapeutic for Brain Tumor Immunotherapy
$543,119John H Sampson · Duke University · R01 · FY2018 · CA
TRANSLATIONAL CLINICAL TRIALS FOR PRIMARY CNS TUMORS
$543,088David Reardon · Duke University · P50 · FY2010 · NS
Mammalian models for integrated metabolic and molecular profiling of malignant glioma
$543,028David A. Nathanson · University Of California Los Angeles · R01 · FY2022 · CA
Regulatory Network Differences/Diverse Tumor Subtypes/Design Combinatorial Therap
$542,875Chris Sander · Sloan-Kettering Inst Can Research · U54 · FY2014 · CA
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma
$542,873Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2024 · CA
Leveraging Biologically Specific PET/MRI Monitoring and Therapeutic Modulation of the Hypoxic Glioblastoma Tumor Immune Microenvironment into Improved Outcomes
$542,641Ramon Francisco Barajas · Oregon Health & Science University · R37 · FY2025 · CA
Exploring the Therapeutic Potential of Stem Cell Biology in Gliomas
$542,555Howard Fine · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Ionic Liquid-Coated NIR-II Polymer Conjugates as Targeted Brain Theranostics
$542,484Davita L. Watkins · Ohio State University · R01 · FY2022 · EB
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients
$542,479James M Markert · University Of Alabama At Birmingham · R01 · FY2019 · CA
Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs
$542,459Gabriele Bergers · University Of California, San Francisco · R01 · FY2010 · CA
Study the role(s) of p53 in embryonic stem cells
$542,071Jing Huang · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Manipulating normal estrogen physiology as a therapeutic approach in cancer
$542,002Donald P McDonnell · Duke University · R01 · FY2025 · CA
CHRONIC CONVECTION ENHANCED DELIVERY (CED) OF TOPOTECAN FOR GLIOBLASTOMA
$541,974Jeffrey N Bruce · Columbia University Health Sciences · R01 · FY2015 · CA
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma
$541,645Vinay K Puduvalli · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Novel functions of ESRRB in glioblastoma
$541,618Rebecca B Riggins · Georgetown University · R01 · FY2024 · CA
Integration of 5-ALA Fluorescence Lifetime Imaging with Stereotactic Surgical Navigation for Quantitative Real-Time Spatial Localization of Tumor During Neurosurgical Procedures
$541,601Orin Bloch · University Of California At Davis · R01 · FY2025 · CA
The roles of p53 in embryonic stem cells
$541,591Jing Huang · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019
$541,558Peter W. Stacpoole · University Of Florida · R01 · FY2021 · FD
NANOTECHNOLOGIES FOR QUANTITATING PI3-KINASE PATHWAY BIOMARKERS
$541,478Charles L Sawyers · California Institute Of Technology · U54 · FY2009 · CA
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
$541,408Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2019 · CA
Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs
$541,356Douglas Hanahan · University Of California, San Francisco · R01 · FY2009 · CA
Calcium Channels in Glioblastoma
$541,211Roger Abounader · University Of Virginia · R01 · FY2022 · NS